Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All drugs

Olutasidenib

Stage Phase 2

Sponsor Rigel Pharmaceuticals

Route oral

Modality small molecule

Class mutant IDH1 inhibitor

Target IDH1 R132 (mutant)

Sources

publication, as of 2026-11-07

https://pmc.ncbi.nlm.nih.gov/articles/PMC9825299/

de la Fuente MI et al. Olutasidenib (FT-2102) in IDH1-mutant relapsed or refractory glioma. Neuro-Oncology 2023;25:146-156. PMC9825299 (NCT03684811)

Brief source I10

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT03684811

A Phase 1b/2 Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT06161974

Phase 2 Study of Olutasidenib With Temozolomide as Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

Olutasidenib Phase 1/2 (glioma cohort)

Registry NCT03684811

Phase Phase 1/2

Status Completed

Enrollment 93

Start 2018-11-01

Primary completion 2021-05-24

Study completion 2022-06-13

Olutasidenib 150 mg BID

Dose 150 mg

Regimen twice daily

Population relapsed or refractory IDH1-mutant glioma (26 enrolled, 25 evaluable)

Estimand Single arm

objective response rate: 8%, 2 of 25

disease control rate: 48%, 12 of 25

grade 3 to 4 ALT increase: 12%

grade 3 to 4 AST increase: 12%

NCT06161974

Registry NCT06161974

Phase Phase 2

Status Recruiting

Enrollment 60

Start 2025-02-01

Primary completion 2029-06

Study completion 2035-06

Catalyst Primary completion. 06.2029. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.